Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jul 30:3:21.
doi: 10.21037/tbcr-22-31. eCollection 2022.

Comments to the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022

Masakazu Toi  1 , Masahiro Takada  1
Affiliations
Editorial

Comments to the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022

Masakazu Toi et al. Transl Breast Cancer Res. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tbcr.amegroups.com/article/view/10.21037/tbcr-22-31/coif). M Takada received research grants from Eisai, Yakult and Medbis, and honorarium from Chugai, AstraZeneca, Daiichi Sankyo, Lilly, Eisai, Nipponkayaku, Pfizer, and Mitaka Khoki. M Toi reports research grants from Chugai, Takeda, Pfizer, Taiho, JBCRG assoc., KBCRN assoc., Eisai, Eli Lilly, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, Shionogi, GL Science, Sanwa Shurui, and honorarium from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly, MSD, Exact Science, Novartis, Shimadzu, Yakult, Nippon Kayaku, Devicore medical Japan. M Toi is a member of advisory board of Daiichi-Sankyo, Eli Lilly, BMS, Athenex Oncology, Bertis, Terumo, Kansai Medical Net, the board of directors (no salary) of JBCRG association, Organisation for Oncology and Translational Research, Kyoto Breast Cancer Research Network, the associate editor of British Journal of Cancer, Scientific Reports, Breast Cancer Research and Treatment, Cancer Science, Frontiers in Women’s Cancer, Asian Journal of Surgery, Asian Journal of Breast Surgery, and the deputy editor of International Journal of Oncology. M Toi serves as an unpaid editorial board member of Translational Breast Cancer Research from December 2021 to November 2023. The authors have no other conflicts of interest to declare.

References

    1. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019;380:617-28. 10.1056/NEJMoa1814017 - DOI - PubMed
    1. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016;17:791-800. 10.1016/S1470-2045(16)00163-7 - DOI - PubMed
    1. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015;372:134-41. 10.1056/NEJMoa1406281 - DOI - PMC - PubMed
    1. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med 2017;377:122-31. 10.1056/NEJMoa1703643 - DOI - PMC - PubMed
    1. Tolaney SM, Tayob N, Dang C, et al. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol 2021;39:2375-85. 10.1200/JCO.20.03398 - DOI - PubMed

Publication types